Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses.
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.